Coexistence of diffuse large B-cell lymphoma, acute myeloid leukemia, and untreated lymphoplasmacytic lymphoma/waldenström macroglobulinemia in a same patient: A case report

Table 1 Immunophenotype of bone marrow and chest wall tumor

Expression	Molecular marker
The immunophenotype of BMMNCs by flow cytometry
Group A	49.64%
Expression	CD34, CD13, CD117
Partial expression	CD33, HLA-DR
No expression	CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD19, CD20, CD36, CD56, CD64, CD23
Group B	22.21%
Expression	CD19, CD20, Kappa
Partial expression
No expression	CD103, CD25, CD11c, CD34, CD117, CD5, CD10, CD23, lambda
The immunohistochemical analysis of bone marrow biopsy
Expression	CD10, CD20, CD34, CD43, CD117, PAX-5, MPO, silver dyeing
Partial expression
No expression	BCL-6, CD3, CD5, MPO
The immunohistochemical analysis of chest wall tumor
Expression	Ki-67 (70%), CD20, PAX-5, CD10, MUM-1, BCL-6, c-MYC (< 40%), BCL-2 (< 50%)
Partial expression
No expression	CD3, CK-pan, TTF, NapsinA, CK7, P40, CK5/6, Syn, CgA, CD56, EBER

BMMNCs: Bone marrow mononuclear cells; MPO: Myeloperoxidase.

Table 2 Abnormalities of genes from bone marrow mononuclear cells

Expression	Abnormality
The mutation of genes
MYD88	p.L265P (14.8%)
TP53	p.N29Kfs*14 (27.3%)
TP53	p.S215N (27.2%)
The fusion of genes or gene expression
WT1	Positive
BIRC2-ARAP1	Positive
The copy number variations
chr2p25.3p13.3	2.56
chr5q14.3q34	1.46
chr8p23.3p21.2	4.30
chr8q21.3q24.3	2.55
chr11q12.1q14.1	3.05
chr11q14.1q22.1	1.43
chr11q22.3q23.1	1.44
chr11q23.1q25	4.85
chr13q12.3q14.13	1.43
chr13q21.1q22.1	2.63
chr13q31.1q31.3	2.49